Olema Pharmaceuticals (OLMA) director sells 10,000 shares of stock

Rhea-AI Filing Summary

Olema Pharmaceuticals director Cyrus Harmon reported a sale of company stock. On January 20, 2026, he sold 10,000 shares of Olema Pharmaceuticals common stock at a weighted average price of $26.88 per share, with individual trade prices ranging from $26.85 to $26.96. Following this transaction, he directly held 727,770 common shares.

The filing also notes an additional 117,028 common shares held indirectly through Harmon Family Investors LLC, where Harmon serves as manager, reflecting his indirect beneficial ownership interest alongside his direct holdings.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Harmon Cyrus

(Last) (First) (Middle)

C/O OLEMA PHARMACEUTICALS, INC.

780 BRANNAN ST

(Street)

SAN FRANCISCO CA 94103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Olema Pharmaceuticals, Inc. [ OLMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		S		10,000	D	$26.88(1)	727,770	D
Common Stock								117,028	I(2)	See Footnote

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. 2. The weighted average sale price for the transaction reported was $26.88, and the range of prices were between $26.85 and $26.96. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.

2. The shares are held by the Harmon Family Investors LLC, of which the Reporting Person is the manager.

	/s/ Shane Kovacs, Attorney-in-Fact	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Olema Pharmaceuticals (OLMA) disclose in this Form 4?

The filing shows that director Cyrus Harmon sold 10,000 shares of Olema Pharmaceuticals common stock on January 20, 2026 in an open-market transaction coded "S."

At what price did Cyrus Harmon sell Olema Pharmaceuticals (OLMA) shares?

The reported weighted average sale price was $26.88 per share, with actual trade prices ranging between $26.85 and $26.96 during the transaction.

How many Olema Pharmaceuticals shares does Cyrus Harmon own after this transaction?

After the reported sale, Cyrus Harmon directly owned 727,770 shares of Olema Pharmaceuticals common stock, according to the Form 4 disclosure.

What indirect holdings in Olema Pharmaceuticals (OLMA) are associated with Cyrus Harmon?

The Form 4 reports an additional 117,028 Olema common shares held indirectly through Harmon Family Investors LLC, of which Cyrus Harmon is the manager.

What does the price range disclosure in the Olema (OLMA) Form 4 mean?

The filing explains that the $26.88 figure is a weighted average sale price, and that individual trades occurred between $26.85 and $26.96; detailed breakdowns are available to the SEC, the issuer, or any shareholder on request.

What is Cyrus Harmon’s relationship to Olema Pharmaceuticals (OLMA)?

The Form 4 identifies Cyrus Harmon as a director of Olema Pharmaceuticals, Inc., with both direct and indirect beneficial ownership of the company’s common stock.